BAY-2402234 (CAT: I019879) is a selective inhibitor of dihydroorotate dehydrogenase (DHODH) developed for the treatment of myeloid malignancies. DHODH is a crucial enzyme involved in the de novo pyrimidine synthesis pathway. By inhibiting DHODH, BAY-2402234 disrupts the production of pyrimidine nucleotides, essential building blocks for DNA and RNA synthesis. This targeted inhibition of DHODH holds therapeutic potential in the treatment of myeloid malignancies, such as certain forms of leukemia.
| Catalog Number | I019879 |
| CAS Number | 2225819-06-5 |
| Molecular Formula | C₂₁H₁₈ClF₅N₄O₄ |
| Purity | 95% |
| Reference | [1]. Andreas Janzer, et al. Abstract DDT02-04: BAY 2402234: A novel, selective dihydroorotate dehydrogenase (DHODH) inhibitor for the treatment of myeloid malignancies. AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. |
